CONCLUSION: Cannabidiol may hold benefit for anxiety-related disorders. Controlled clinical studies are needed.
Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to trigger a “high” or alter consciousness.
A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including:
Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical studies of CBD exist in the psychiatric literature.
Unlike some past studies which showed that CBD helped to reduce anxiety at higher dosage levels (300mg/day), this study showed that patients were able to reduce their anxiety with as little as 25mg/day.